The Global Lomeprol API Market was valued at US$ 65.3 Million in 2025 and is projected to reach US$ 89.7 Million by 2034, growing at a Compound Annual Growth Rate (CAGR) of 3.8% during the forecast period (2025–2034). This steady growth is driven by the increasing global demand for diagnostic imaging procedures, the rising prevalence of chronic diseases requiring precise diagnostics, and advancements in contrast-enhanced imaging technologies across healthcare facilities.

As the medical imaging industry evolves toward higher precision and patient safety, the focus intensifies on the key Active Pharmaceutical Ingredient (API) manufacturers who are ensuring the supply of high-purity, reliable contrast media. In this blog, we profile the Top 10 Companies in the Lomeprol API Industry—a group of specialized pharmaceutical manufacturers and chemical suppliers shaping the future of diagnostic imaging agents.

Download FREE Sample Report:
Lomeprol API Market – View in Detailed Research Report

---

🔟 1. Spin S. p. A

Headquarters: Milan, Italy
Key Offering: Lomeprol API (Purity ≥99%), Custom Synthesis Services

Spin S. p. A is a leading European manufacturer of advanced pharmaceutical intermediates and APIs, with a strong focus on iodinated contrast media. The company’s expertise in complex organic synthesis makes it a critical supplier for global pharmaceutical companies producing Lomeprol-based injectable solutions.

Quality and Innovation Initiatives:

• State-of-the-art cGMP compliant manufacturing facilities

• Continuous process optimization for enhanced purity and yield

• Robust R&D pipeline for next-generation contrast media APIs

Download FREE Sample Report:
Lomeprol API Market – View in Detailed Research Report

---

9️⃣ 2. Zhejiang Starry Pharmaceutical Co., Ltd.

Headquarters: Taizhou, Zhejiang, China
Key Offering: High-Purity Lomeprol API, Contrast Media Intermediates

Zhejiang Starry Pharmaceutical is a major player in the Asian API market, specializing in contrast media agents. The company has established a significant global footprint, supplying Lomeprol API to formulation manufacturers across multiple continents with a strong emphasis on cost-effectiveness and scalability.

Quality and Innovation Initiatives:

• Vertically integrated production from raw materials to finished API

• Expansion of manufacturing capacity to meet growing international demand

• Strategic partnerships with global pharmaceutical distributors

---

8️⃣ 3. Sichuan Ren’an Pharmaceutical Co., Ltd.

Headquarters: Chengdu, Sichuan, China
Key Offering: Lomeprol API, Iodinated Contrast Media Portfolio

Sichuan Ren’an Pharmaceutical has developed a strong reputation for quality in the contrast media API sector. The company’s rigorous quality control systems and commitment to regulatory compliance have positioned it as a trusted supplier for both domestic and international markets.

Quality and Innovation Initiatives:

• Advanced purification technologies ensuring API consistency

• Compliance with multiple international pharmacopoeia standards

• Investment in green chemistry principles for sustainable manufacturing

---

7️⃣ 4. Bracco Imaging S.p.A.

Headquarters: Milan, Italy
Key Offering: Lomeprol API for proprietary formulations, Diagnostic Imaging Solutions

While primarily known as a finished dosage form manufacturer, Bracco Imaging maintains significant API manufacturing capabilities for its proprietary contrast agents, including Lomeprol. The company’s vertical integration strategy ensures tight control over the entire supply chain from API to final product.

Quality and Innovation Initiatives:

• Proprietary synthesis routes for enhanced API characteristics

• Extensive clinical research supporting product efficacy and safety

• Global regulatory expertise across all major markets

---

6️⃣ 5. Hovione

Headquarters: Loures, Portugal
Key Offering: Lomeprol API Development and Manufacturing, Particle Engineering Services

Hovione brings extensive experience in API development and manufacturing to the contrast media market. The company’s technological capabilities in particle size control and crystallization are particularly valuable for optimizing the performance characteristics of Lomeprol in final formulations.

Quality and Innovation Initiatives:

• Expertise in handling complex organic molecules with iodine content

• Comprehensive analytical method development and validation

• Integrated CDMO services from preclinical to commercial scale

Download FREE Sample Report:
Lomeprol API Market – View in Detailed Research Report

---

5️⃣ 6. Interpharma Praha a.s.

Headquarters: Prague, Czech Republic
Key Offering: Lomeprol API, Custom Synthesis of Contrast Media Agents

Interpharma Praha has established itself as a reliable European supplier of contrast media APIs, leveraging its historical expertise in iodine chemistry. The company serves both generic and innovative pharmaceutical companies with high-quality Lomeprol API.

Quality and Innovation Initiatives:

• Modern manufacturing facilities with significant capacity

• Strong focus on environmental, health, and safety standards

• Strategic location providing efficient logistics across Europe

---

4️⃣ 7. SUNWAY PHARMA

Headquarters: Shanghai, China
Key Offering: Lomeprol API, Pharmaceutical Intermediates

SUNWAY PHARMA is an emerging player in the contrast media API market, combining competitive manufacturing capabilities with growing international regulatory experience. The company is expanding its presence in global markets through strategic quality investments and customer partnerships.

Quality and Innovation Initiatives:

• Investment in advanced purification and isolation technologies

• Expansion of regulatory filings in key international markets

• Development of cost-effective manufacturing processes

---

3️⃣ 8. Alfa Chemistry

Headquarters: New York, USA
Key Offering: Lomeprol API for Research, Analytical Standards

Alfa Chemistry serves the research and development segment of the market, providing high-purity Lomeprol API for method development, analytical testing, and preclinical studies. The company supports pharmaceutical companies and research institutions with reliable reference materials.

Quality and Innovation Initiatives:

• Comprehensive analytical characterization services

• Support for regulatory submission documentation

• Custom synthesis for novel contrast agent development

---

2️⃣ 9. Hangzhou Hyper Chemicals Limited

Headquarters: Hangzhou, Zhejiang, China
Key Offering: Lomeprol API, Pharmaceutical Fine Chemicals

Hangzhou Hyper Chemicals has developed specialized expertise in contrast media chemistry, positioning itself as a growing supplier in the Asian API market. The company focuses on maintaining competitive advantages through process innovation and quality consistency.

Quality and Innovation Initiatives:

• Continuous improvement of synthetic routes for efficiency

• Strategic focus on contrast media as a core competency

• Expansion of quality management system certifications

---

1️⃣ 10. Shanghai UCHEM Inc.

Headquarters: Shanghai, China
Key Offering: Lomeprol API, Custom Manufacturing Services

Shanghai UCHEM completes our list as a specialized manufacturer with capabilities in contrast media API production. The company’s technical expertise and manufacturing flexibility make it a valuable partner for pharmaceutical companies requiring reliable Lomeprol supply.

Quality and Innovation Initiatives:

• Technical support for formulation development

• Scale-up capabilities from laboratory to commercial production

• Commitment to meeting evolving regulatory requirements

Get Full Report Here:
Lomeprol API Market – View in Detailed Research Report

---

🔬 Outlook: The Future of Lomeprol API Is Precision and Regulatory Excellence

The Lomeprol API market is undergoing a significant transformation. While established suppliers continue to dominate, the industry is witnessing increased regulatory scrutiny, technological advancements in manufacturing, and growing demand for higher purity standards.

📈 Key Trends Shaping the Market:

• Stringent regulatory requirements driving quality upgrades across manufacturing facilities

• Growing preference for Purity ≥99% APIs to ensure final product safety and efficacy

• Increasing outsourcing of API manufacturing to specialized CDMOs with contrast media expertise

• Expansion of contrast-enhanced imaging applications in emerging diagnostic fields

Get Full Report Here:
Lomeprol API Market – View in Detailed Research Report

The companies listed above are not only supplying critical imaging agents—they’re enabling advanced medical diagnostics that improve patient outcomes worldwide.